文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

大剂量地塞米松治疗COVID-19相关急性呼吸窘迫综合征:随机对照试验方案结构化摘要

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-08-26

本研究为多中心、随机、对照、开放标签、平行组临床试验,计划纳入284例18岁以上、确诊SARS-CoV-2感染并符合ARDS诊断、机械通气至少72小时的ICU患者,比较标准治疗联合大剂量地塞米松与单纯标准治疗的有效性和安全性。主要结局为28天内无呼吸机天数,次要结局包括28天和90天死亡率、院内感染频率、SOFA评分变化、俯卧位、病毒排出及ICU出院时谵妄和肌无力。

要点

  • 大剂量地塞米松方案为16 mg/24小时×5天,随后8 mg/24小时×5天。
  • 主要结局为28天内无呼吸机天数,样本量按组间差异3天、均值9天、标准差9天估算为284例。
  • 试验为开放标签设计,按中心分层区组随机1:1分配。

核心结论

  • 方案拟评估大剂量地塞米松治疗SARS-CoV-2肺炎继发ARDS的有效性与安全性,目前处于招募阶段,尚未报告结果。

研究设计与样本

  • 多中心、随机、对照、开放标签、平行组临床试验,计划纳入284例成人COVID-19相关ARDS患者,按中心分层1:1区组随机。

主要发现

  • 原文为研究方案摘要,未报告试验结果数据。

关键数值与推荐

  • 纳入标准包括年龄≥18岁、RT-PCR确诊SARS-CoV-2感染、PaO2/FiO2<300且呼气末正压≥5 cm H2O并双肺浸润、机械通气至少72小时。
  • 干预组地塞米松16 mg/24小时用5天,随后8 mg/24小时用5天;对照组地塞米松不超过6 mg/24小时用不超过10天。
  • 主要结局为28天内无呼吸机天数;样本量按组间差异3天、均值9天、标准差9天、80%把握度、双侧α=0.05估算为284例(每组142例)。

临床怎么用

  • 该方案为ICU成人COVID-19相关ARDS患者使用大剂量地塞米松提供了随机对照试验框架,结果出来前不能据此改变临床用药。
  • 方案明确了纳入排除标准、给药方案和主要结局定义,可作为同类试验设计参考。

局限性

  • 原文仅为研究方案摘要,无疗效和安全性结果;开放标签设计可能影响部分主观结局判断。
  • 试验尚在招募,计划2021年12月底完成,结果尚未产生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia. TRIAL DESIGN: Multicentre, randomized clinical trial, controlled, open label, parallel group, to evaluate the effectiveness and safety of high dose dexamethasone in adult patients with confirmed COVID-19, with Acute Respiratory Distress Syndrome. PARTICIPANTS: We will include patients with SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome, in several intensive care units (ICU) in Buenos Aires, Argentina (CEMIC, Clinica Bazterrica, Sanatorio Sagrado Corazon) Inclusion criteria: Men and women, age ≥ 18 years old. Confirmed diagnosis of SARS-CoV-2 infection, by RT-PCR. Diagnosis of Acute Respiratory Distress Syndrome (hypoxemic respiratory failure not explained by cardiac disease + PaO2/FiO2 ratio < 300 with a Positive End-Expiratory Pressure ≥ 5 cm H2O + bilateral pulmonary infiltrates) Length of mechanical ventilation of at least 72 hours Informed consent (next of kin / legal guardian) Exclusion criteria: Pregnant or breast-feeding women. Terminal disease (advanced cancer; under palliative care; cardiovascular, respiratory, or renal disease with a life expectancy less ≤ 1 year). Therapeutic limitation (advance directives or do not resuscitate order) Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents, active cancer). Patients under chronic treatment with glucocorticoids for other diseases (≥ 8 mg prednisone, or equivalent) Participation in another randomized clinical trial. INTERVENTION AND COMPARATOR: Eligible patients will be randomized to receive standard ICU patient care (group 1) or standard ICU patient care plus high dose dexamethasone (group 2). Group 1: dexamethasone up to 6 mg/24 hours for up to 10 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines. Group 2: dexamethasone 16 mg/24 hours for 5 days followed by dexamethasone 8 mg/24 hours for 5 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines. MAIN OUTCOME: The main result is ventilator-free days at 28 days (Days without ventilator support in the first 28 days following randomization). Secondary outcomes are 28-days and 90-days mortality, frequency of nosocomial infections in the first 28 days after randomization, Sequential Organ Failure Assessment (SOFA) score variation and prone position in the first 10-days, viral shedding 28-days after randomization, and delirium and muscle weakness at ICU discharge. RANDOMISATION: Treatment will be assigned according to site stratified randomization by permuted random blocks sequence 1:1 generated with a table in R language concealed in a randomization tool in REDCap (Research Electronic Data CAPture) platform. BLINDING (MASKING): This is an open trial, so no masking of treatment assignment will be used. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Assuming a 3 days difference in ventilator-free days between treatment groups, with a mean of 9 days, and a standard deviation of 9 days; the necessary sample size would be 284 subjects (142 per group), with a power of 80% and a two-tailed alpha error of 0.05. TRIAL STATUS: The protocol with code 1264, version 3.0 on date: May 13, 2020 is approved by the local Ethics Committee. The trial is in the recruitment phase. Recruitment began May 22, 2020 and is anticipated to be complete by the end of December 2021. TRIAL REGISTRATION: The trial was registered under the title "Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial" with ClinicalTrials number NCT04395105, https://clinicaltrials.gov/ct2/show/NCT04395105 , registered on 20 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Maskin LP, Olarte GL, Palizas F, et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32843098. doi:10.1186/s13063-020-04646-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。